Key result
Transfusion of normal AT-III concentrate led to a striking clinical recovery in a 31-year-old woman with progressing ischemic stroke and homozygous variant antithrombin III.
Why the study?
Does transfusion of normal AT-III concentrate improve clinical recovery in a patient with progressing ischemic stroke and homozygous variant AT-III?
Case Report (n=14)
Does transfusion of normal AT-III concentrate improve clinical recovery in a patient with progressing ischemic stroke and homozygous variant AT-III?
Homozygous variant antithrombin III is a potential cause of ischemic stroke in young adults that can be effectively treated with AT-III concentrate.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for AT-III transfusion in homozygous variant antithrombin III stroke; prospective trials needed before clinical adoption.
Ueyama et al. (1989) conducted a case report in Progressing ischemic stroke and familial variant of antithrombin III (n=14). Transfusion of normal AT-III concentrate was evaluated on Clinical recovery. Transfusion of normal AT-III concentrate led to a striking clinical recovery in a 31-year-old woman with progressing ischemic stroke and homozygous variant antithrombin III.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: